Alimera Sciences, Inc. (ALIM): Price and Financial Metrics
GET POWR RATINGS... FREE!
ALIM Stock Summary
- ALIMERA SCIENCES INC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than only 3.62% of US listed stocks.
- With a one year PEG ratio of 0.14, ALIMERA SCIENCES INC is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than only 2.34% of US stocks.
- ALIM's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of just 3.29% of US stocks.
- Stocks that are quantitatively similar to ALIM, based on their financial statements, market capitalization, and price volatility, are FALC, DESP, CMCM, CLRO, and NH.
- Visit ALIM's SEC page to see the company's official filings. To visit the company's web site, go to www.alimerasciences.com.
ALIM Valuation Summary
- In comparison to the median Healthcare stock, ALIM's price/sales ratio is 89.47% lower, now standing at 0.2.
- ALIM's price/sales ratio has moved NA NA over the prior 157 months.
Below are key valuation metrics over time for ALIM.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| ALIM | 2023-03-24 | 0.2 | -0.5 | -0.5 | -3.7 |
| ALIM | 2023-03-23 | 0.2 | -0.6 | -0.5 | -3.8 |
| ALIM | 2023-03-22 | 0.2 | -0.5 | -0.5 | -3.7 |
| ALIM | 2023-03-21 | 0.2 | -0.6 | -0.6 | -3.9 |
| ALIM | 2023-03-20 | 0.2 | -0.6 | -0.6 | -3.9 |
| ALIM | 2023-03-17 | 0.2 | -0.6 | -0.6 | -3.9 |
ALIM Growth Metrics
- Its 5 year cash and equivalents growth rate is now at -54.15%.
- Its year over year revenue growth rate is now at 25.71%.
- Its 3 year price growth rate is now at -71.58%.
The table below shows ALIM's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 54.059 | -14.407 | -18.433 |
| 2022-06-30 | 52.614 | -15.226 | -17.359 |
| 2022-03-31 | 59.713 | -6.936 | -6.679 |
| 2021-12-31 | 59.029 | -3.224 | -4.372 |
| 2021-09-30 | 58.844 | 1.196 | -1.243 |
| 2021-06-30 | 59.164 | 1.78 | 2.322 |
ALIM Price Target
For more insight on analysts targets of ALIM, see our ALIM price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $14.83 | Average Broker Recommendation | 1.5 (Moderate Buy) |
ALIM Stock Price Chart Interactive Chart >
ALIM Price/Volume Stats
| Current price | $1.90 | 52-week high | $7.92 |
| Prev. close | $1.89 | 52-week low | $1.30 |
| Day low | $1.90 | Volume | 1,895 |
| Day high | $1.94 | Avg. volume | 21,506 |
| 50-day MA | $2.21 | Dividend yield | N/A |
| 200-day MA | $4.32 | Market Cap | 13.29M |
Alimera Sciences, Inc. (ALIM) Company Bio
Alimera Sciences, Inc., a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States, Germany, the United Kingdom, and internationally. It focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. Its ILUVIEN is inserted in the back of the patient's eye in a non-surgical procedure, which allows for a self-sealing wound by delivering a continuous microdose of the non-proprietary corticosteroid fluocinolone acetonide in the eye. The company has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of proprietary insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. It sells its products through direct sales and distributors. The company serves physician offices, pharmacies, and hospitals. Alimera Sciences, Inc. was founded in 2003 and is headquartered in Alpharetta, Georgia.
Latest ALIM News From Around the Web
Below are the latest news stories about ALIMERA SCIENCES INC that investors may wish to consider to help them evaluate ALIM as an investment opportunity.
Alimera Improves Capital Structure, Strengthens Balance Sheet and Extends Term Loan FacilityRepurchases Series A Preferred Stock, eliminating $24 million liquidation preference for approximately $938,000Completes $12 million private placement of preferred stock and warrants with conversion price and exercise price at 55% premium to the closing share price on March 24, 2023Extends maturity of existing credit facility to April 2028 and interest-only period up to 3 years ATLANTA, March 27, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical |
Alimera Sciences to Report Fourth Quarter and Full Year 2022 Financial Results on Friday, March 31, 2023, and Provide Corporate UpdateConference Call to be held Friday, March 31, at 9:00am Eastern TimeATLANTA, March 24, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces today that it will report fourth quarter and full year 2022 financial results on Friday, March 31, 2023, before the market opens. Management will host a confer |
Alimera Appoints Roger Sawhney, M.D. to Its Board of DirectorsATLANTA, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announces the addition of Roger Sawhney, M.D. to its Board of Directors. Dr. Sawhney is presently the Chief Financial Officer for Garuda Therapeutics, a company creating off-the-shelf, durable blood stem cell therapies. Dr. Sawhn |
Alimera Announces Submission of Marketing Authorization Application in Switzerland for ILUVIEN®Switzerland is latest market for Alimera in continued geographic expansionATLANTA, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces that its distribution partner, Horus Pharma S.A.S. (Horus) through its Swiss affiliate Horus Pharma Suisse SA, has filed a marketing authorization appl |
Alimera Sciences Appoints Industry Veteran Russell L. Skibsted as Chief Financial OfficerRussel Skibsted 2MB Russell Skibsted, CFO of Alimera Sciences Russell Skibstead Hi-Res Russell Skibsted, CFO of Alimera Sciences ATLANTA, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, today announced the appointment of pharma financial veteran Russell L. Skibsted, as Senior Vice President |
ALIM Price Returns
| 1-mo | -11.63% |
| 3-mo | -29.89% |
| 6-mo | -62.60% |
| 1-year | -63.67% |
| 3-year | -47.37% |
| 5-year | -87.70% |
| YTD | -29.89% |
| 2022 | -47.17% |
| 2021 | 21.56% |
| 2020 | -44.33% |
| 2019 | -29.62% |
| 2018 | -46.02% |
Continue Researching ALIM
Want to do more research on Alimera Sciences Inc's stock and its price? Try the links below:Alimera Sciences Inc (ALIM) Stock Price | Nasdaq
Alimera Sciences Inc (ALIM) Stock Quote, History and News - Yahoo Finance
Alimera Sciences Inc (ALIM) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...